Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (86)	6/22/2001 3:08:45 AM
From: nigel bates	Respond to of 222

TOKYO, June 21 /PRNewswire/ -- Kirin Brewery Co., Ltd. and Corixa Corporation (Nasdaq: CRXA - news) today announced an agreement to discover and develop fully human antibody therapeutics. Kirin will provide Corixa its TC Mouse(TM) technology, including the KM Mouse(TM) which was co-developed by Kirin and Medarex, Inc., to create human antibodies to multiple target antigens from Corixa's extensive library of autoimmune disease, cancer and infectious disease antigens. Under the terms of the agreement, Corixa has option rights to exclusively develop and commercialize human antibody products created using the TC Mouse(TM) technology. In return, Kirin will receive certain license fees and milestone payments as well as royalties on commercial sales of antibody products from Corixa. Kirin also retains a first negotiation right to develop and commercialize Corixa's antibody products from this alliance in Asia. Kirin's TC Mouse(TM) technology is a transchromosomic mouse system that uses transferred human chromosome fragments carrying 100% of the variable and constant region sequences found in the natural human immunoglobulin gene sequences. Kirin's TC Mouse(TM) technology has also been distributed to pharmaceutical and biotech companies, including Novo Nordisk, Schering-Plough, ZymoGenetics, and NovImmune through its strategic partner, Medarex. ``We are very excited by this opportunity to provide our TC Mouse(TM) technology to Corixa. This partnership is an indication of Kirin's superior human antibody technology. With this partnership, we will be able to expand our activities in the field of fully human antibody business,'' said Katsuhiko Asano, Ph.D., president of Kirin's Pharmaceutical Division. ``Our collaboration with Kirin represents another opportunity for Corixa to extend the reach of our expansive technology base,'' said Steven Gillis, Ph.D., chairman and chief executive officer at Corixa. ``This partnership expands our ability to generate human antibodies, speeding up the development of new product candidates Powered by Corixa(TM).'' About Kirin Kirin is Japan's foremost beer producer which ranks eighth largest in the world by sales volume. Its pharmaceutical division is applying its knowledge of biotechnology to the development of advanced pharmaceutical products in the fields of renal diseases, cancer and hematological diseases, and immunological and allergy-related diseases. Kirin's recombinant DNA- based ESPO® (erythropoietin) and GRAN® (G-CSF), co-developed with Amgen, have annual sales exceeding $400 million in Asia. Kirin's pharmaceutical division is now enhancing its activities on human antibody and cell therapy. Kirin has developed the original TC Mouse(TM) technology for fully human antibody development. Kirin has also assembled a broad platform of patented technologies for fully human antibody development with a strategic alliance with Medarex including Medrex's HuMAb Mouse(TM) technology. Kirin creates and develops fully human antibodies for itself and offers its customers TC Mouse(TM), HuMAb Mouse(TM) and KM Mouse(TM)...